Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness

NCT ID: NCT00913328

Last Updated: 2009-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-08-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Leukotriene receptor antagonists appear to posses additive anti-inflammatory effects to the effect of inhaled corticosteroids.

Hypothesis: Treatment with oral montelukast will lower the dose-response plateau to inhaled methacholine in patients with mild to moderate persistent asthma treated with a stable dose of inhaled corticosteroids.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Montelukast

Oral montelukast 10 mg once daily for 12 weeks

Group Type ACTIVE_COMPARATOR

Montelukast (Singulair)

Intervention Type DRUG

10 mg tablet once daily

Placebo

Oral placebo once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral placebo once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Montelukast (Singulair)

10 mg tablet once daily

Intervention Type DRUG

Placebo

Oral placebo once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Singulair

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smoking adults with mild to moderate persistent asthma:

* FEV1 \> 70 % pred
* PD20 methacholine \< 3.9 mmol
* treated for at least 3 months with a stable dose of inhaled corticosteroids
* Documented dose-response plateau to inhaled methacholine on two occasions
* Males and non-pregnant females

Exclusion Criteria

* Asthma medication other than inhaled corticosteroids and inhaled b2-agonists
* Viral respiratory tract infections within the 3 weeks prior to enrollment
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hvidovre University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Heart and Lung Diseases, Hvidovre Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zuzana Diamant, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Charlotte S Ulrik, MD, DMSc

Role: PRINCIPAL_INVESTIGATOR

Dept. of Heart and Lung Diseases, Hvidovre Hospital, Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SINGDEN-04-2002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Montelukast With Status Asthmaticus, Ages 6-18
NCT00494572 UNKNOWN PHASE2/PHASE3